PharmaLectures.com

Courses › GMP, GDP, quality and compliance › OOS and OOT results: the investigation an inspector expects, not the retest they dread

OOS and OOT results: the investigation an inspector expects, not the retest they dread

Your team investigates failing results once, correctly, so batches leave quarantine.

An OOS investigation is the documented inquiry a laboratory must run when a test result falls outside the approved specification. The best known guidance is the FDA guidance on investigating out-of-specification test results, revised in 2022, which splits the work into a Phase I laboratory investigation and, if no lab error is proven, a Phase II full-scale investigation covering manufacturing. In Europe, Chapter 6 of the EU GMP guide requires OOS results to be investigated and documented. This course shows what inspectors expect, including out-of-trend results.

  • 6 audio modulesthree lengths each
  • 1 h to 5 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • QC, QAwho it is written for

Why OOS investigation training matters

An analyst gets an out-of-specification (OOS) result and runs the sample again. The retest passes, nothing is written down, and the Food and Drug Administration (FDA) inspector writes a Form 483 observation. The batch sits in quarantine while quality assurance rebuilds the story.

What changes after this course

Your analysts secure the original sample and open a Phase I investigation before anyone prepares a new one. Your quality assurance reviewers receive reports that name a root cause and carry the raw data. You hold a certificate for every learner and a training record for each person.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

OOS investigation training: what this course gives your people

The analyst who sees a failing result stops and secures the original sample and preparations. A Phase I laboratory investigation starts under the FDA Guidance for Industry on OOS results, and no new sample is prepared until each step is documented. Your team can tell a confirmed OOS from a result that a documented, assignable laboratory error invalidates.

Your quality assurance reviewers approve Phase II reports on the first pass, because the root cause is named and the raw data sits behind it. When the laboratory is not at fault, your team brings in manufacturing and engineering, as the FDA guidance expects and as European Union Good Manufacturing Practice (EU GMP) Chapter 6 requires OOS results to be investigated. Analyst error stops being the default answer.

Retesting, resampling and averaging decisions are written down with their reasons, in line with Title 21 of the Code of Federal Regulations (CFR) Part 211. When an inspector asks why a second vial was tested, the answer is already in the file, and nobody has to reconstruct it from memory.

Corrective and preventive action plans now target the process that failed, and trending of out-of-trend results shows the drift while the batch still passes. The inspector reads your final report, finds the verdict in the first paragraph, checks the attached raw data and moves on to the next item.

Who needs OOS investigation training

  • Quality Control Analyst

    A result lands outside specification and the fastest move is to run it again. You get a clear record of what to write down, and what to leave untouched, before any new sample is prepared.

  • Quality Assurance Specialist

    A report arrives that blames human error and offers no proof. You get a standard for sending it back and asking for the root cause that the evidence actually supports.

  • Laboratory Manager

    An auditor asks why a failing result was averaged with a passing one. You get the retesting and resampling rules your team follows, so the answer is already written down.

  • Head of Quality Operations

    You sign a batch release that depends on a closed investigation. You get reports built to the FDA guidance and EU GMP Chapter 6, so your signature rests on a file that holds up.

Roles: Quality assurance and Qualified Person, Quality control and laboratory

Businesses: every kind of pharma company

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: any jurisdiction

Courses are in English. Other languages on request.

After this course your people can

  1. Classify a laboratory result as out-of-specification, out-of-trend or atypical using your own documented procedures.
  2. Carry out a Phase I laboratory investigation, and record each step, before any retest begins.
  3. Write a Phase II full-scale investigation report that names the actual root cause and cites the raw data behind it.
  4. Decide when resampling is justified by applying 21 CFR Part 211 and the FDA guidance on OOS results.
  5. Draft a corrective and preventive action plan that stops a specific laboratory error from repeating.
  6. Defend an investigation decision to an auditor by citing the FDA guidance and EU GMP Chapter 6.
  7. Reject an investigation report that blames human error without evidence, and say what is missing.

What the company gets

  • Your quality control laboratory stops creating hidden Form 483 observations through undocumented retests.
  • Batch release stays on schedule because OOS investigations close correctly the first time.
  • Inspectors receive reports that answer their questions before they have to ask them.
  • You hold a certificate for each learner, a recorded multiple-choice questionnaire per module and a training record for each person, ready for the next audit.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 6 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard2 h 30 min25 min a module, for regulatory, quality and business-development staff
Expanded5 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Quality assurance and Qualified PersonExpanded5 h
Quality control and laboratoryExpanded5 h

OOS investigation course outline: 6 modules

6 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Classify OOS and out-of-trend results by FDA and European guidelines

    • Why an aberrant value is not yet an OOS result, and the one step that tells the two apart.
    • How to spot an out-of-trend drift in the data and escalate it while the batch still passes.
    • What to do in the first minutes after an unexpected result, before anyone discards a solution.
  2. 2Run a Phase I laboratory investigation before anyone touches a new sample

    • The checklist that rules out calibration, dilution and technique faults before any new sample.
    • Why a retest without a documented assignable cause becomes a Form 483 observation.
    • How to write the Phase I assessment so the supervisor can sign it the same day.
  3. 3Lead a Phase II full-scale investigation to the real root cause

    • When Phase II stays in the lab and when manufacturing and engineering must join the table.
    • How to follow the evidence from the failing result back to the step that caused it.
    • Why analyst error is not a root cause, and the question that gets you to the real one.
  4. 4Apply FDA rules to decide on retesting, resampling and averaging

    • How to resample under the FDA guidance without being accused of testing into compliance.
    • When averaging results is acceptable and when it hides a failing value.
    • What to do when an analyst wants to discard the failing data and test another vial.
  5. 5Write investigation reports an auditor accepts on the first read

    • How to put the verdict in the first paragraph so the inspector stops searching for it.
    • The raw data and audit trail extracts that make an investigation report stand on its own.
    • Why a report that ends in unknown error invites a rejected batch and a warning, and what to write instead.
  6. 6Build Corrective and Preventive Action (CAPA) plans that stop repeat OOS

    • How to write a CAPA that changes the laboratory process instead of retraining one analyst.
    • The effectiveness checks that show an auditor your corrective action worked.
    • Why trending OOS and out-of-trend data exposes a weak method before it becomes a deviation.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about OOS investigation training

Can a laboratory simply retest after an OOS result?

No. Retesting until a passing result appears, sometimes called testing into compliance, is exactly what inspectors look for. The FDA OOS guidance allows a retest only when a defined investigation justifies it, under a written procedure that fixes in advance how many retests will be done and how results are judged. An original result can only be invalidated when an assignable laboratory error is documented.

What is the difference between OOS and OOT?

An out-of-specification result falls outside the approved acceptance criteria, so the batch cannot be released without an investigation. An out-of-trend result is still within specification but does not follow the expected pattern, for example in a stability study, and may warn of a future failure. OOS has firm regulatory expectations; OOT relies on the company's own trending procedure, which inspectors also review.

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

6 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h in the briefing length and 5 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for QC, QA. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 54 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team